Mouse models of severe combined immunodeficiencies
Mouse models of severe combined immunodeficiencies
批准号:
7614101
负责人:
Frederick W. Alt
金额:
$47.73万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-07-05 至 2014-06-30
关键词:
Abelson murine leukemia virusAffectAgeAntibodiesB-Cell DevelopmentB-LymphocytesBostonCell CountCell LineCellsChildCodeCollaborationsComplexDNADNA DamageDNA ligase IVDataDefectDevelopmentDiseaseEmbryoEventFamily ResearchFibroblastsFloorFundingGenesGenomic InstabilityGenomicsGoalsHumanHuman ResourcesImmuneImmune responseImmune systemImmunityImmunodeficiency and CancerImmunoglobulin Class SwitchingImmunoglobulin Switch RecombinationImmunologic Deficiency SyndromesIncidenceInfectionInstructionIonizing radiationKnock-in MouseLIG4 geneLaboratoriesLast NameLeadLigaseLymphocyteMalignant NeoplasmsMature B-LymphocyteModelingMusMutant Strains MiceMutationNamesNeurologicNeuronsOncogenicPaste substancePathway interactionsPatientsPediatric HospitalsPhenotypePoint MutationPredispositionPrincipal InvestigatorProcessProteinsRadiation ToleranceRadioResearchResearch PersonnelRoleSevere Combined ImmunodeficiencyStagingStem cellsSyndromeSystemT-Cell DevelopmentT-Cell LeukemiaT-LymphocyteTumor Suppressor ProteinsV(D)J Recombinationartemisbasecell typeembryonic stem cellhuman diseaseimmunodeficient mouse modelin vivointerestlymphoid neoplasmmouse modelmutantnovelnull mutationprogramsprotein functionrepairedresponsetumortumorigenesis
中文摘要
点击翻译按钮获取中文摘要
英文摘要
V(D)J recombination defects underlie diseases ranging from immunodeficiency and auto-immunity
to cancer. Human SCIDs result either from defects in T cell development or both T and B cell development.
The latter disease, referred to as T'B'SCID, generally results from V(D)J recombination defects. Null
mutations in RAG-1 or RAG-2 are the basis for about half of the human TB'SCIDs. Hypomorphic RAG
mutations also cause Omenn syndrome (OS), a rare autosomal recessive SCID that often presents as a
"complex" immunodeficiency with an auto-immune component. Mechanisms by which RAG mutations lead
to OS are unknown. A major aim of this application is to elucidate normal RAG functions and aberrant RAG
activities that could lead to complex immunodeficiency and cancer by characterizing RAG mutant mouse
lines. We have generated mice that lack both the "non-core" RAG1 and RAG2 regions implicated in
suppressing transpositions and a mouse carrying a RAG1 point mutation that has a potential joining defect
that may predispose to oncogenic translocations. We will continue analyses of these mice and also
generate additional RAG knock-in mutations including several proposed to allow RAG cutting but impaired
joining. We also will employ a novel Abelson Murine Leukemia virus (A-MuLV)-transformed pro-B cell line
system as a rapid in vivo screen for mutations of interest and as a basis for mechanistic analyses of RAG
protein functions. The other half of human TB'SCIDs have normal RAG proteins; but show V(D)J
recombination defects and increased ionizing radiation-sensitivity. The defects underlying this subset are
mutations in genes that encode the Artemis, XLF and DMALigase 4 non-homologous DMA end-joining
factors. Human Artemis mutations completely inactivate the gene; whereas human Lig4 mutations are all
hypomorphic. It is not yet clear whether known human XLF mutations completely inactivate the gene. We
previously generated a mouse model for Artemis deficiency and recently generated mouse models for both
XLF and hypomorphic Ligase 4 deficiency. The other major aims of this proposal are to characterize these
new models to elucidate normal functions of these NHEJ factors and, again, to determine how mutations in
these genes contribute to various human immunodeficiency syndromes and potentially to cancer.
Our immune system recognizes and eliminates a vast array of foreign invaders based on a process
in which limitless numbers of antibody genes are formed by cutting and pasting gene cassettes. Defects in
human genes that code for proteins that carry out this cutting and pasting process cause immunodeficiency
(susceptibility to infection). Our proposed research seeks to make mouse models for such human diseases
to better understand the functions of the cutting and pasting proteins and to develop better therapies.
Children's Hospital
Karp Family Research Laboratories
9th Floor
One Blackfan Circle
Boston, MA 02115
PHS 398 (Rev. 04/06) Page Form Page 2
Principal Investigator/Program Director (Last, First, Middle): TeitlOrst, ComeliS P.I Alt, Frederick W.
KEY PERSONNEL. See instructions. Use continuation pages as needed to provide the required information in the format shownbelow.
Start with Principal Investigator(s). List all other key personnel in alphabetical order, last name first.
Name eRA CommonsUser Name Organization Role onProject
Alt, Frederick W. FREDALT Children'
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role of DNA Double Strand Break Response in Suppression of Thymic Lymphoma
-
批准号:7780950
-
项目类别:
-
资助金额:$44.71万
-
财政年份:2010
-
负责人:Frederick W. Alt
-
依托单位:
Mechanisms that Regulate Antibody Class Switch Recombination and Somatic Hypermutation
-
批准号:10392890
-
项目类别:
-
资助金额:$53.1万
-
财政年份:2008
-
负责人:Frederick W. Alt
-
依托单位:
Molecular Mechanisms of Class Switch Recombination
-
批准号:8386894
-
项目类别:
-
资助金额:$40.08万
-
财政年份:2008
-
负责人:Frederick W. Alt
-
依托单位:
Molecular Mechanisms of Class Switch Recombination
-
批准号:7743798
-
项目类别:
-
资助金额:$42.36万
-
财政年份:2008
-
负责人:Frederick W. Alt
-
依托单位:
AID Targeting Mechanisms for IgH Switch Recombination and Somatic Hypermutation
-
批准号:9228317
-
项目类别:
-
资助金额:$44.25万
-
财政年份:2008
-
负责人:Frederick W. Alt
-
依托单位:
Mechanisms that Regulate Antibody Class Switch Recombination and Somatic Hypermutation
-
批准号:10612752
-
项目类别:
-
资助金额:$53.1万
-
财政年份:2008
-
负责人:Frederick W. Alt
-
依托单位:
Molecular Mechanisms of Class Switch Recombination
-
批准号:7577240
-
项目类别:
-
资助金额:$42.33万
-
财政年份:2008
-
负责人:Frederick W. Alt
-
依托单位:
Molecular Mechanisms of Class Switch Recombination
-
批准号:8197214
-
项目类别:
-
资助金额:$42.63万
-
财政年份:2008
-
负责人:Frederick W. Alt
-
依托单位:
Molecular Mechanisms of Class Switch Recombination
-
批准号:7995253
-
项目类别:
-
资助金额:$42.23万
-
财政年份:2008
-
负责人:Frederick W. Alt
-
依托单位:
AID Targeting Mechanisms for IgH Switch Recombination and Somatic Hypermutation
-
批准号:8697880
-
项目类别:
-
资助金额:$43.85万
-
财政年份:2008
-
负责人:Frederick W. Alt
-
依托单位:
Molecular Mechanism of Translocations in B-Cell Lymphoma
-
批准号:7156133
-
项目类别:
-
资助金额:$40.2万
-
财政年份:2006
-
负责人:Frederick W. Alt
-
依托单位:
T Cell Development
-
批准号:6742737
-
项目类别:
-
资助金额:$0.87万
-
财政年份:2004
-
负责人:Frederick W. Alt
-
依托单位:
Role of H2AX and ATM in Suppression of Thymic Lymphomas
-
批准号:6989691
-
项目类别:
-
资助金额:$38.75万
-
财政年份:2004
-
负责人:Frederick W. Alt
-
依托单位:
Towards a Mouse Model of Classical Hodgkin's Disease and PTLD
-
批准号:8220847
-
项目类别:
-
资助金额:$50.14万
-
财政年份:2003
-
负责人:Frederick W. Alt
-
依托单位:
Towards a Mouse Model of Classical Hodgkin's Disease and PTLD
-
批准号:8444354
-
项目类别:
-
资助金额:$45.76万
-
财政年份:2003
-
负责人:Frederick W. Alt
-
依托单位:
Towards a Mouse Model of Classical Hodgkin's Disease and PTLD
-
批准号:8029601
-
项目类别:
-
资助金额:$49.01万
-
财政年份:2003
-
负责人:Frederick W. Alt
-
依托单位:
ROLE OF VAV AND ITS EFFECTORS IN LYMPHOCYTE ACTIVATION
-
批准号:6496054
-
项目类别:
-
资助金额:$22.05万
-
财政年份:2001
-
负责人:Frederick W. Alt
-
依托单位:
ROLE OF VAV AND ITS EFFECTORS IN LYMPHOCYTE ACTIVATION
-
批准号:6346235
-
项目类别:
-
资助金额:$42.66万
-
财政年份:2000
-
负责人:Frederick W. Alt
-
依托单位:
MURINE MODELS OF SEVERE COMBINED IMMUNODEFICIENCIES
-
批准号:6332448
-
项目类别:
-
资助金额:$27.63万
-
财政年份:2000
-
负责人:Frederick W. Alt
-
依托单位:
Molecular Mechanisms of Class Switch Recombination
-
批准号:6344608
-
项目类别:
-
资助金额:$18.51万
-
财政年份:2000
-
负责人:Frederick W. Alt
-
依托单位:
海外基金